FDA Grants Fast Track Status to AI-Developed Mesothelioma Inhibitor ISM6331

Insilico Medicine's AI-driven pan-TEAD inhibitor, ISM6331, has received Fast Track Designation from the FDA. This designation aims to expedite the development and review of the drug for adult patients with advanced malignant pleural mesothelioma that has progressed after prior therapies. The Fast Track status acknowledges the drug's potential to address a significant unmet medical need for this aggressive cancer.